Gastrointestinal Cancer News

Study findings showed that patients with HIV who are coinfected with HPV and Chlamydia trachomatis face a substantially increased risk for high-grade anal intraepithelial neoplasia, suggesting that C. trachomatis may enhance the oncogenic potential of HPV, researchers said.

Children with hepatoblastoma resected at diagnosis demonstrated disease control with a minimal postoperative chemotherapy regimen, according to results from a phase 3 Children’s Oncology Group trial published in The Lancet Oncology.

The prevalence of anal high-grade squamous intraepithelial lesions, or HSILs, is 27% among women with HIV in the Unites States, and researchers said that “it is likely” the prevalence is “much higher than previously estimated,” based on findings from the AIDS Malignancy Consortium 084 study.

The Targeted Agent and Profiling Utilization Registry , or TAPUR, study is fulfilling a need in clinical research across the United States for patients with advanced cancers that have actionable genomic variants, according to Richard L. Schilsky, MD, FACP, FASCO, ASCO senior vice president and chief medical officer.

A combination of encorafenib, binimetinib and cetuxumab significantly improved OS and overall response rate compared with standard-of-care chemotherapy among patients with BRAF V600E-mutant metastatic colorectal cancer, according to findings from the randomized phase 3 BEACON CRC study presented at ESMO World Congress on Gastrointestinal Cancer.

Flexible dosing of regorafenib improved quality of life for patients with metastatic colorectal cancer without sacrificing efficacy, according to results from the randomized phase 2 REARRANGE trial presented at ESMO World Congress on Gastrointestinal Cancer.

The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so until the next great advancement occurs. Meanwhile, companies like Fate Therapeutics are going all-in on their own versions of immune effector cell therapies to treat cancer.

Eating fatty or lean fish or shellfish as part of a regular diet may help decrease the risk for colorectal cancer, according to study results.

SAN DIEGO — Patients who receive antibiotic treatment for Helicobacter pylori infection experience gastric cancer at rates higher than the general population, and several risk factors can increase that risk even further, according to data presented at Digestive Disease Week.

In this Guest Commentary, Diana L. Hanna, MD, assistant professor of clinical medicine at the University of Southern California’s Norris Comprehensive Cancer Center, discusses results of the KEYNOTE-062 study and the potential role of pembrolizumab as an alternative to chemotherapy in the frontline setting for advanced gastric or gastroesophageal junction cancer.